Immunogenicity of infliximab and adalimumab

Measurement of Serum Antibodies to Infliximab and Adalimumab

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these se...

2.04.84 Measurement of Serum Antibodies to Infliximab and Adalimumab

2.04.84 Measurement of Serum Antibodies to Infliximab and Adalimumab

2.04.84 Measurement of Serum Antibodies to Infliximab and Adalimumab

Effectiveness of infliximab after adalimumab failure in Crohn's disease.

AIM To evaluate the effectiveness of infliximab as a second-line therapy in Crohn's disease patients after adalimumab failure. METHODS A historical cohort study in a community-based gastroenterology practice evaluated Crohn's disease patients treated with infliximab (induction plus maintenance) after adalimumab failure. Patients were identified using a large Spanish database (ENEIDA). RESUL...